Zobrazeno 1 - 10
of 177
pro vyhledávání: '"Susan W. Barnett"'
Autor:
Beatriz Perdiguero, Benedikt Asbach, Carmen E. Gómez, Josef Köstler, Susan W. Barnett, Marguerite Koutsoukos, Deborah E. Weiss, Anthony D. Cristillo, Kathryn E. Foulds, Mario Roederer, David C. Montefiori, Nicole L. Yates, Guido Ferrari, Xiaoying Shen, Sheetal Sawant, Georgia D. Tomaras, Alicia Sato, William J. Fulp, Raphael Gottardo, Song Ding, Jonathan L. Heeney, Giuseppe Pantaleo, Mariano Esteban, Ralf Wagner
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
To control HIV infection there is a need for vaccines to induce broad, potent and long-term B and T cell immune responses. With the objective to accelerate and maintain the induction of substantial levels of HIV-1 Env-specific antibodies and, at the
Externí odkaz:
https://doaj.org/article/6036c61a4c684d169531306cb6b2b597
Autor:
Joseph R. Francica, Daniel E. Zak, Caitlyn Linde, Emilio Siena, Carrie Johnson, Michal Juraska, Nicole L. Yates, Bronwyn Gunn, Ennio De Gregorio, Barbara J. Flynn, Nicholas M. Valiante, Padma Malyala, Susan W. Barnett, Pampi Sarkar, Manmohan Singh, Siddhartha Jain, Margaret Ackerman, Munir Alam, Guido Ferrari, Andres Salazar, Georgia D. Tomaras, Derek T. O'Hagan, Alan Aderem, Galit Alter, Robert A. Seder
Publikováno v:
Blood Advances, Vol 1, Iss 25, Pp 2329-2342 (2017)
Abstract: Adjuvants have a critical role for improving vaccine efficacy against many pathogens, including HIV. Here, using transcriptional RNA profiling and systems serology, we assessed how distinct innate pathways altered HIV-specific antibody resp
Externí odkaz:
https://doaj.org/article/412a4dcf39fe46fa94a258dc035552c8
Autor:
Zihao Wang, Clarisse Lorin, Marguerite Koutsoukos, David Franco, Babak Bayat, Ying Zhang, Andrea Carfi, Susan W. Barnett, Frederick Porter
Publikováno v:
Vaccines, Vol 4, Iss 2, p 17 (2016)
Two HIV-1 subtype C gp120 protein candidates were the selected antigens for several experimental vaccine regimens now under evaluation in HVTN 100 Phase I/II clinical trial aiming to support the start of the HVTN 702 Phase IIb/III trial in southern A
Externí odkaz:
https://doaj.org/article/84d9a0f80d4b4066b1c89084392fde7f
Autor:
Yingxia Wen, Hung V Trinh, Christine E Linton, Chiara Tani, Nathalie Norais, DeeAnn Martinez-Guzman, Priyanka Ramesh, Yide Sun, Frank Situ, Selen Karaca-Griffin, Christopher Hamlin, Sayali Onkar, Sai Tian, Susan Hilt, Padma Malyala, Rushit Lodaya, Ning Li, Gillis Otten, Giuseppe Palladino, Kristian Friedrich, Yukti Aggarwal, Celia LaBranche, Ryan Duffy, Xiaoying Shen, Georgia D Tomaras, David C Montefiori, William Fulp, Raphael Gottardo, Brian Burke, Jeffrey B Ulmer, Susan Zolla-Pazner, Hua-Xin Liao, Barton F Haynes, Nelson L Michael, Jerome H Kim, Mangala Rao, Robert J O'Connell, Andrea Carfi, Susan W Barnett
Publikováno v:
PLoS ONE, Vol 13, Iss 4, p e0194266 (2018)
The RV144 Phase III clinical trial with ALVAC-HIV prime and AIDSVAX B/E subtypes CRF01_AE (A244) and B (MN) gp120 boost vaccine regime in Thailand provided a foundation for the future development of improved vaccine strategies that may afford protect
Externí odkaz:
https://doaj.org/article/c524038f512c48a39e68e221debb900c
Autor:
Iskra Tuero, Venkatramanan Mohanram, Thomas Musich, Leia Miller, Diego A Vargas-Inchaustegui, Thorsten Demberg, David Venzon, Irene Kalisz, V S Kalyanaraman, Ranajit Pal, Maria Grazia Ferrari, Celia LaBranche, David C Montefiori, Mangala Rao, Monica Vaccari, Genoveffa Franchini, Susan W Barnett, Marjorie Robert-Guroff
Publikováno v:
PLoS Pathogens, Vol 11, Iss 8, p e1005101 (2015)
Many viral infections, including HIV, exhibit sex-based pathogenic differences. However, few studies have examined vaccine-related sex differences. We compared immunogenicity and protective efficacy of monomeric SIV gp120 with oligomeric SIV gp140 in
Externí odkaz:
https://doaj.org/article/03dd5126b48944a0890b2f5773c2155f
Autor:
Russell Vassell, Yong He, Prasad Vennakalanti, Antu K Dey, Min Zhuang, Wei Wang, Yide Sun, Zohar Biron-Sorek, Indresh K Srivastava, Celia C LaBranche, David C Montefiori, Susan W Barnett, Carol D Weiss
Publikováno v:
PLoS ONE, Vol 10, Iss 6, p e0128562 (2015)
The membrane proximal external region (MPER) of the gp41 subunit of the HIV-1 envelope glycoprotein (Env) contains determinants for broadly neutralizing antibodies and has remained an important focus of vaccine design. However, creating an immunogen
Externí odkaz:
https://doaj.org/article/2dbc550b61bf4314aa375f1a7113ff50
Autor:
Philip Kotze, Fatima Laher, Mary Allen, Peter B. Gilbert, Jia J. Kee, Dishiki Jenny Kalonji, Carter Bentley, Susan W. Barnett, Tricia Philip, Craig Innes, Adrian Puren, Holly Janes, Millicent Atujuna, Nivashnee Naicker, M. Juliana McElrath, Philisiwe B. Makhoba, Gladys Kobane, Girisha Kistnasami, Katlego S. Mapetla, Zakir Gaffoor, Cleon N. Ncayiya, Sanjay Phogat, Vimla Naicker, Simbarashe Takuva, James G. Kublin, Linda-Gail Bekker, Nima S. Hejazi, David Benkeser, Niranjan Kanesa-thasan, Modulakgotla Sebe, Olivier Van Der Meeren, Yunda Huang, Bontle Modibedi, Pamela Mda, Mookho Malahleha, Mpho Sikhosana, Matsontso Mathebula, Pearl Selepe, Amy Ward, Lawrence Corey, Megan Jones, John Hural, Tania Adonis, Sheetal Kassim, Carlos Diaz Granados, Nicole Grunenberg, Shelly Ramirez, Doug Grove, Maphoshane Nchabeleng, Brittany Prigmore, Graeme Meintjes, Erica Lazarus, William Brumskine, Lubbe Wiesner, Nigel Garrett, Marguerite Koutsoukos, Thozama Dubula, Zoe Moodie, Glenda Gray, Nishanta Singh, Michele P. Andrasik
Publikováno v:
The New England journal of medicine. 384(12)
Background A safe, effective vaccine is essential to eradicating human immunodeficiency virus (HIV) infection. A canarypox-protein HIV vaccine regimen (ALVAC-HIV plus AIDSVAX B/E) showed modest efficacy in reducing infection in Thailand. An analogous
Autor:
Aemro Kassa, Antu K Dey, Pampi Sarkar, Celia Labranche, Eden P Go, Daniel F Clark, Yide Sun, Avishek Nandi, Karin Hartog, Heather Desaire, David Montefiori, Andrea Carfi, Indresh K Srivastava, Susan W Barnett
Publikováno v:
PLoS ONE, Vol 8, Iss 10, p e76139 (2013)
Entry of HIV-1 into target cells requires binding of the viral envelope glycoprotein (Env) to cellular receptors and subsequent conformational changes that culminates in fusion of viral and target cell membranes. Recent structural information has rev
Externí odkaz:
https://doaj.org/article/b7c0af66bfd14154b3573bb1a9e8c474
Autor:
Xiaoying Shen, Fatima Laher, Zoe Moodie, Rachel L. Spreng, Georgia D. Tomaras, Sanjay Phogat, Vijay L. Mehra, Michael Pensiero, Susan W. Barnett, Nicole Grunenberg, M. Juliana McElrath, Peter B. Gilbert, Mary Allen, Glenda Gray, Nicole L. Yates, Linda-Gail Bekker, Lawrence Corey, Olivier Van Der Meeren, Arthur S. McMillan, Ying Huang
Publikováno v:
Scientific Reports
Scientific Reports, Vol 10, Iss 1, Pp 1-14 (2020)
Scientific Reports, Vol 10, Iss 1, Pp 1-14 (2020)
In the RV144 trial, vaccine-induced V1V2 IgG correlated with decreased HIV-1 risk. We investigated circulating antibody specificities in two phase 1 poxvirus prime-protein boost clinical trials conducted in South Africa: HVTN 097 (subtype B/E) and HV
Autor:
Antu K Dey, Brian Burke, Yide Sun, Klara Sirokman, Avishek Nandi, Karin Hartog, Ying Lian, Anthony R Geonnotti, David Montefiori, Michael Franti, Grégoire Martin, Andrea Carfi, Pascal Kessler, Loïc Martin, Indresh K Srivastava, Susan W Barnett
Publikováno v:
PLoS ONE, Vol 7, Iss 1, p e30233 (2012)
The identification of HIV-1 envelope glycoprotein (Env) structures that can generate broadly neutralizing antibodies (BNAbs) is pivotal to the development of a successful vaccine against HIV-1 aimed at eliciting effective humoral immune responses. To
Externí odkaz:
https://doaj.org/article/8de4cde9f4c94164b95e696ae0582869